Halozyme diversifies in drug delivery with Surf Bio buy

Halozyme has expanded its portfolio of drug delivery technologies for a second time in a few months with the acquisition of Surf Bio for up to $400m.

Setback for MSD as German court blocks Keytruda SC launch

A court in Germany has granted an injunction that will prevent MSD from distributing the new, subcutaneous version of its cancer drug Keytruda.

Halozyme abandons its €2bn pursuit of Evotec

Halozyme Therapeutics has withdrawn its offer to acquire Evotec, saying that the German company had been unwilling to engage with negotiations

Pair of R&D updates bolster GSK ahead of investor meeting

GlaxoSmithKline (GSK) has reported encouraging data for its COVID-19 antibody sotrovimab, and an alliance with Halozyme to develop a new generation of long-acting HIV drugs, as it prepares

Halozyme abandons cancer R&D as lead drug failed